National guideline concordance and outcomes for pathologic N2 disease in non-small cell lung cancer.

ABSTRACT:

Background

Real-world treatment practices for positive mediastinal nodal disease in non-small cell lung cancer (NSCLC) continues to vary despite guidelines. We aim to assess national trends in the treatment of pathologic-N2 disease, and evaluate the association with clinical nodal staging and timing of systemic therapy.

Methods

The National Cancer Database was queried for patients with NSCLC who underwent lobectomy and had pathologic-N2 disease from 2010-2017. National Comprehensive Cancer Network (NCCN) guideline concordance was evaluated. cN2 patients were analyzed based on timing of systemic therapy and response. Multivariable logistic regression evaluated outcomes by type of systemic therapy. Survival analysis utilized Cox proportional hazards regression and Kaplan-Meier

SUBMITTER: Mitzman B 

PROVIDER: S-EPMC9186219 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature